Guardant Health shares are traded on Nasdaq, Mizuho raised its price target, and FDA approval spurred a positive market reaction.
5 reports, 3 independent
Updated Aug 14
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Guardant Health shares are traded on Nasdaq, Mizuho raised its price target, and FDA approval spurred a positive market reaction.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Director sold Guardant Health shares while Mizuho raised its price target.1 source
Guardant Health market activity, including Mizuho rating upgrades and FDA approval, is underway.1 source
Keep exploring
The entities involved
-
Guardant Health
American biotechnology company
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Mizuho Securities lifted its price target and disclosed a transaction involving Guardant Health in an SEC filing.
- Mizuho Securities set a price objective on the stock of Assembly Biosciences, Inc., which trades on the Nasdaq stock exchange.
- ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.